The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...

HUTCHMED has advanced its ongoing study of surufatinib and camrelizumab for treatment‑naïve metastatic pancreatic ductal ...

Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of ...

Zenas BioPharma has announced positive findings from its phase 3 INDIGO trial evaluating obexelimab in patients with ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Funding to accelerate development of AI-driven tumour profiling tool OneMap One Biosciences has secured €15 million in Series A financing to expand its AI-powered single-cell transcriptomic platform, ...

Foundation’s test to be used in Oxford-led blood biomarker trial The Food for the Brain Foundation’s Cognitive Function Test is set to play a central role in the UK-based ‘READ OUT’ trial, which is ...

The scheme could give NHS patients access to new antibiotics as early as 2022 A government scheme to fuel the development of new antibiotics by offering to pay pharmaceutical companies upfront for ...

Six new treatments aim to improve patient outcomes across key areas Hikma Pharmaceuticals and Celltrion Inc. have signed exclusive licensing agreements to introduce six biosimilar treatments across ...

Ionis Pharmaceuticals has shared positive top-line results from a late-stage study of olezarsen in hypertriglyceridaemia. The phase 3 Essence trial, conducted with Ionis’ research partner the TIMI ...

New MHRA–FDA collaboration aims to boost patient access and AI safety Patients in the UK are set to benefit from a strengthened partnership between the Medicines and Healthcare products Regulatory ...